TY - JOUR
T1 - Prevalence of Comorbidity between Dry Eye and Allergic Conjunctivitis
T2 - A Systematic Review and Meta‐Analysis
AU - Akasaki, Yasutsugu
AU - Inomata, Takenori
AU - Sung, Jaemyoung
AU - Nakamura, Masahiro
AU - Kitazawa, Koji
AU - Shih, Kendrick Co
AU - Adachi, Takeya
AU - Okumura, Yuichi
AU - Fujio, Kenta
AU - Nagino, Ken
AU - Midorikawa‐inomata, Akie
AU - Kuwahara, Mizu
AU - Hirosawa, Kunihiko
AU - Huang, Tianxiang
AU - Morooka, Yuki
AU - Shokirova, Hurramhon
AU - Eguchi, Atsuko
AU - Murakami, Akira
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - This systematic review aimed to determine the comorbid dry eye (DE) and allergic conjunctivitis (AC) prevalence. We searched PubMed and EMBASE for articles published until 22 March 2022, combining the terms “(dry eye OR keratoconjunctivitis sicca) AND allergic conjunctivitis.” Study‐specific estimates (DE and AC incidence rates among patients with AC and DE, respectively) were combined using the one‐group meta‐analysis in a random‐effects model. The initial search yielded 700 studies. Five articles reporting AC incidence among individuals with DE and six articles reporting DE incidence among individuals with AC were included in the qualitative synthesis. In these nine articles, the total sample size was 7254 patients. The DE incidence among individuals with AC was 0.9–97.5%; the AC incidence among individuals with DE was 6.2–38.0%. One‐group meta‐analysis using a random‐effects model showed that 47.2% (95% confidence interval: 0.165–0.779; 320/1932 cases) of patients with AC had comorbid DE and 17.8% (95% confidence interval: 0.120–0.236; 793/4855 cases) of patients with DE had comorbid AC, as defined by each article. Complimentary screening and treatment for patients with DE and AC may improve long‐term outcomes and prevent chronic ocular damage in highly susceptible populations.
AB - This systematic review aimed to determine the comorbid dry eye (DE) and allergic conjunctivitis (AC) prevalence. We searched PubMed and EMBASE for articles published until 22 March 2022, combining the terms “(dry eye OR keratoconjunctivitis sicca) AND allergic conjunctivitis.” Study‐specific estimates (DE and AC incidence rates among patients with AC and DE, respectively) were combined using the one‐group meta‐analysis in a random‐effects model. The initial search yielded 700 studies. Five articles reporting AC incidence among individuals with DE and six articles reporting DE incidence among individuals with AC were included in the qualitative synthesis. In these nine articles, the total sample size was 7254 patients. The DE incidence among individuals with AC was 0.9–97.5%; the AC incidence among individuals with DE was 6.2–38.0%. One‐group meta‐analysis using a random‐effects model showed that 47.2% (95% confidence interval: 0.165–0.779; 320/1932 cases) of patients with AC had comorbid DE and 17.8% (95% confidence interval: 0.120–0.236; 793/4855 cases) of patients with DE had comorbid AC, as defined by each article. Complimentary screening and treatment for patients with DE and AC may improve long‐term outcomes and prevent chronic ocular damage in highly susceptible populations.
KW - allergic conjunctivitis
KW - comorbidity rate
KW - complementary treatment
KW - dry eye
KW - meta‐analysis
KW - perennial allergic conjunctivitis
KW - seasonal allergic conjunctivitis
KW - systematic review
UR - http://www.scopus.com/inward/record.url?scp=85132434161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132434161&partnerID=8YFLogxK
U2 - 10.3390/jcm11133643
DO - 10.3390/jcm11133643
M3 - Review article
AN - SCOPUS:85132434161
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 13
M1 - 3643
ER -